David Gerber
Professor · RTOG Foundation · University of Texas Southwestern Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Gerber as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03808558 · Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung CarcinomasDavid E Gerber · active not recruiting · KRAS Gene Mutation · principal investigator
- Ph3NCT02768558 · Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLCRTOG Foundation, Inc. · terminated · Non-Small Cell Lung Cancer · principal investigator
- N/ANCT02758054 · Patient Navigation for Lung Cancer Screening in an Urban Safety-Net SystemUniversity of Texas Southwestern Medical Center · completed · Non-Small Cell Lung Carcinoma, Compliance Behavior, Prevention Harmful Effects · principal investigator
- N/ANCT02335333 · Biomarkers of Aging as Predictors of Kidney Transplant FunctionSapere Bio · completed · Delayed Graft Function, Other Complications of Kidney Transplant · principal investigator
- Ph3NCT02201992 · Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)ECOG-ACRIN Cancer Research Group · active not recruiting · ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive · principal investigator
- N/ANCT00619216 · Myfortic Conversion Trial in OLT Recipients With GI IntoleranceUniversity of North Carolina, Chapel Hill · completed · GI Disturbance · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- UT Southwestern NCI National Clinical Trials Network LAPSUG1CA233302 · NCI · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2019 to 2026 · $923,608 awarded in 2026Same name and institution; not confirmed by an ID
- UT Southwestern Simmons Comprehensive Cancer Center Clinical Oncology Research Career Development AwardK12CA289567 · NCI · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2025 to 2026 · $580,591 awarded in 2026Same name and institution; not confirmed by an ID
- Finding the optimal balance of immunotherapy efficacy and toxicity.U01AI156189 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2020 to 2024 · $543,590 awarded in 2024Same name and institution; not confirmed by an ID
- Development of New Cancer Treatments and InvestigatorsK24CA201543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2016 to 2020 · $117,031 awarded in 2020Same name and institution; not confirmed by an ID
- UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10U10CA180870 · NCI · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2016 to 2018 · $644,932 awarded in 2018Same name and institution; not confirmed by an ID
- Evaluating prior cancer exclusion policy to increase lung cancer trial accrualR03CA191875 · NCI · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2015 to 2016 · $80,959 awarded in 2016Same name and institution; not confirmed by an ID
- Regulating Hepatic Progenitor Cell ProliferationR03DK072215 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2007 to 2008 · $71,540 awarded in 2008Same name and institution; not confirmed by an ID
- HEPATIC PROGENITORS IN TRANSPLANTATIONK08DK059302 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2002 to 2006 · $124,523 awarded in 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT02201992
- NCI NCTN- Network Lead Academic Participating Site: USCU10CA180830 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Anthony Boutros El-Khoueiry, HEINZ JOSEF LENZ, DAVID IAN QUINN · fiscal years 2014 to 2018Named on NCT02201992
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT02201992
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT02201992
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:09 UTC. The ranking covers the 200 most relevant of 79 PubMed records, and a shared surname and initials can bring in a namesake. All 79 on PubMed
- 7,991 citationsRCR 252.7
- Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.JAMA Oncol · 2018914 citationsRCR 33.5
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.Lancet Oncol · 2017797 citationsRCR 23.4
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.J Clin Oncol · 2021568 citationsRCR 28.4
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.J Clin Oncol · 2016439 citationsRCR 12.6
- Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.J Clin Oncol · 2016377 citationsRCR 10.9
- Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.J Clin Oncol · 2011344 citationsRCR 8.0
- Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.J Clin Oncol · 2014245 citationsRCR 7.4
- Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.J Thorac Oncol · 2018167 citationsRCR 4.7
- Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.Lung Cancer · 2020141 citationsRCR 5.6